Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
Saif
Muhammad Wasif
MW
Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA. wasif.saif@yale.edu
Merritt
James
J
Robbins
Joan
J
Stewart
Jeffrey
J
Schupp
Joachim
J
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000378:metabolism; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013940:Thymidylate Synthase / Q000378:metabolism; D014803:Vitamin B Complex / Q000008:administration & dosage
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D009944:Organoplatinum Compounds; D014803:Vitamin B Complex; D000068258:Bevacizumab; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D013940:Thymidylate Synthase; D002955:Leucovorin; D005472:Fluorouracil